Combined statin and fenofibrate therapy and cardiorenal outcomes in patients with CKD, dyslipidemia, and ischemic heart disease

Clicks: 22
ID: 330806
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #47 of 198 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 198 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Adults with non-dialysis-dependent chronic kidney disease (CKD), ischemic heart disease (IHD), and hypertriglyceridemia are at high cardiorenal risk; whether starting fenofibrate together with statin therapy is effective and safe in this population is uncertain. Methods In a multicenter retrospective cohort study emulating a target trial in the TriNetX Global Collaborative Network (2018–2024), 112 003 (28.5%) of 392 969 statin initiators with CKD and hypertriglyceridemia had IHD. Those without dialysis dependence were assigned to statin-fenofibrate combination therapy or statin monotherapy according to fenofibrate initiation within 3 months of the first statin prescription. The main outcomes were expanded major adverse cardiovascular events (MACE: acute myocardial infarction, stroke, heart failure, cardiac arrest, or all-cause death) and end-stage kidney disease (ESKD) necessitating dialysis. Propensity score matching yielded 3 191 pairs. Cox models estimated hazard ratios (HRs). Results Median follow-up was 881 days with combination therapy and 925 days with statin monotherapy. Combination therapy was associated with lower risks of MACE (1 472 [46.1%] vs. 1 576 [49.4%] events; HR, 0.93; 95% CI, 0.86–0.99) and ESKD necessitating dialysis (264 [8.3%] vs. 335 [10.5%]; HR, 0.79; 95% CI, 0.67–0.92). Risks of all-cause mortality (377 vs. 375), acute myocardial infarction (537 vs. 570), heart failure (1,059 vs. 1 134), stroke (310 vs. 312), acute kidney injury (825 vs. 840), and coded safety events were not significantly different between groups. Conclusions Among selected adults with non-dialysis-dependent CKD, hypertriglyceridemia, and IHD, statin-–fenofibrate combination therapy was associated with lower risks of MACE and of ESKD necessitating dialysis, without a significant increase in coded safety events.
Reference Key
openalex_W7215099630 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yen-Chih Chang, Ming‐Hsien Tsai, Yu‐Wei Fang, Meng‐Ting Chen, Ya‐Hui Tseng, Cheng-Chun Wei
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag343
URL
https://doi.org/10.1093/ckj/sfag343
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.